ClinicalTrials.gg
SuspendedNCT06591741Updated Sep 16, 2026

PCA Administration in Prosthetic Joint Infection

An interventional study of Oral PCA in Prosthetic Joint Infection, sponsored by Dr. Dean Reeves Clinic. Suspended at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Dr. Dean Reeves Clinic · Not applicable, Interventional, and Other

How we know

Why this study was suspended
Could not find a collaborating orthopedic surgeon.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Determine if dietary protocatechuic acid (PCA) will affect health biomarkers in patient undergoing revision surgery for a knee prosthetic joint infection

Read the detailed description

Patients who are scheduled to undergo revision surgery for a knee prosthetic joint infection are given PCA prior to surgery for a time period determined by a previous pilot study. PCA is then post-operatively until anticoagulation is stopped, and then will be resumed for four years post revision surgery. Measurement of changes in glucose control, immunity, will be measured over the first 3 months post-revision, and the post-revision reinfection rate over the full 4 years will be compared to a cohort rate

02

Conditions studied

  • Prosthetic Joint Infection
03

In context

Lead sponsor

Dr. Dean Reeves Clinic is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 3 weeks or more after total knee arthroplasty
  • One or more symptoms of infection, including redness, swelling, pain, increasing range of motion loss, fever, nausea, and loss of appetite.
  • WBC count of aspirate >50,000 cells per μL

Exclusion criteria

Exclusion Criteria:

  • Not willing to undergo blood draw at 3 months.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    PCA administraton

    Dietary Supplement: Oral PCA

Interventions

06

What researchers measure

Primary outcomes

  1. Change in immunity factor CXCL9 from 0 to 3 months

    Time frame: 0 and 3 months

  2. Change in HbA1c from 0 to 3 months

    Time frame: 0 and 3 months

Secondary outcomes

  1. Reinfection rate after revision for prosthetic joint infection

    Time frame: 0 to 4 years

07

Study locations

1 site
  • Kenneth Dean Reeves
    Shawnee Mission, Kansas 66205, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Jul 2028, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2024
First posted
Sep 19, 2024
StartEst.
Jan 2027
Primary completionEst.
Jul 2028
CompletionEst.
Dec 2028
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06591741
Lead sponsor
Dr. Dean Reeves Clinic
Responsible party
Dr. Dean Reeves (Primary Investigator, Dr. Dean Reeves Clinic) — Principal investigator
First posted
Sep 19, 2024
Start date
Jan 2027 (estimated)
Primary completion
Jul 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 16, 2026

Study contacts

Kenneth D Reeves, M.D.
principal investigator · K. Dean Reeves, M.D., P.A.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pyrrolidonecarboxylic Acid

Start the discussion